Phytochemicals in Cancer Chemotherapy

A Comprehensive Overview

Introduction

Cancer remains a leading cause of morbidity and mortality worldwide, characterized by the uncontrolled proliferation and spread of abnormal cells. The complexity of this disease necessitates a multifaceted approach to treatment, with chemotherapy serving as a cornerstone in the therapeutic arsenal for many cancer types.1 Chemotherapy, employing various chemical agents, aims to disrupt the growth and division of rapidly dividing cells, a key characteristic of cancer.1 While synthetic drugs have become prevalent in modern medicine, the history of drug discovery is deeply rooted in natural sources, particularly plants, which have provided a wealth of compounds with diverse biological activities, including potent anticancer properties.2 The inherent chemical diversity found within the plant kingdom continues to be a valuable resource for identifying novel therapeutic agents against cancer.

The ongoing challenge of cancer drug resistance and the desire to mitigate the off-target toxicities associated with many conventional chemotherapeutic agents underscore the continuous need to explore new therapeutic avenues. Plant-derived compounds, having evolved over millennia to interact with biological systems, offer a rich source of structurally diverse molecules with potential for anticancer activity.3 Traditional medicine systems across the globe have long utilized plants for their healing properties, including anecdotal evidence of anticancer effects.4 Modern scientific investigation has increasingly validated some of these traditional uses, revealing the specific phytochemicals responsible for the observed therapeutic benefits. Notably, the early successes of plant-derived chemotherapy drugs, such as the vinca alkaloids, in the mid-20th century marked a significant advancement in the treatment of previously intractable hematological malignancies.4 The observation in the 1950s that extracts from the Madagascar periwinkle (Catharanthus roseus) led to a reduction in white blood cell counts in animal models 4 exemplifies how the investigation of traditional remedies or even unexpected biological activities can serendipitously lead to the discovery of potent anticancer agents. This highlights the enduring importance of exploring the diverse biological effects of natural products in the quest for more effective cancer therapies.

This article aims to provide a comprehensive and up-to-date overview of the phytochemicals that are currently recognized as components of approved chemotherapy drugs. The scope will encompass the identification of these drugs, a detailed examination of the specific phytochemicals responsible for their anticancer activity, their mechanisms of action at the molecular level, and a discussion of recent research and emerging trends in the utilization of phytochemicals in cancer therapy.

Identification of Plant-Derived Chemotherapy Drugs

The primary chemotherapy drugs identified through this process as having plant-derived origins include the vinca alkaloids (vincristine, vinblastine, vinorelbine, vindesine, and vinflunine), the taxanes (paclitaxel and docetaxel), the camptothecins (topotecan and irinotecan), and the epipodophyllotoxins (etoposide and teniposide). All vinca alkaloids used in chemotherapy originate from the Madagascar periwinkle (Catharanthus roseus).4 Paclitaxel was initially isolated from the bark of the Pacific yew tree (Taxus brevifolia), while docetaxel is a semi-synthetic derivative of a precursor found in the needles of the European yew (Taxus baccata).4 Topotecan and irinotecan are semi-synthetic derivatives of camptothecin, which was first isolated from the bark of the Chinese happy tree (Camptotheca acuminata).18 Etoposide and teniposide are semi-synthetic derivatives of podophyllotoxin, a lignan found in the roots of the American mayapple (Podophyllum peltatum) and the Himalayan mayapple (Podophyllum hexandrum).4 Additionally, other agents with plant-derived connections include ingenol mebutate (Picato), contained in Euphorbia peplus and used for treating skin cancer 19, and trastuzumab emtansine (Kadcyla), an antibody-drug conjugate utilizing a synthetic derivative of a cytotoxic principle from the Ethiopian plant Maytenus ovatus for breast cancer treatment.19

The observation that a significant portion of these established plant-derived chemotherapy drugs fall into a limited number of structural classes, namely vinca alkaloids, taxanes, camptothecins, and epipodophyllotoxins, suggests that these specific categories of plant secondary metabolites possess inherent chemical and biological properties that have made them particularly amenable for development as effective anticancer agents. This pattern likely reflects the successful evolutionary strategies in plants to produce compounds that can interfere with fundamental cellular processes that are also critical for the proliferation of cancer cells.

Phytochemicals in Established Chemotherapy: Mechanisms of Action

The following table summarizes the plant-derived chemotherapy drugs currently in use, their plant sources, the specific phytochemicals responsible for their activity, and their primary mechanisms of action.

Vinca Alkaloids

The entire class of vinca alkaloids utilized in chemotherapy is derived from the Madagascar periwinkle (Catharanthus roseus).4 The key naturally occurring phytochemicals in this group with significant anticancer activity are vinblastine and vincristine.4 Over time, medicinal chemists have developed semi-synthetic derivatives, including vinorelbine, vindesine, and vinflunine, with the aim of enhancing efficacy and/or reducing the toxicities associated with the parent compounds.4 The fundamental mechanism of action shared by all vinca alkaloids is the disruption of microtubule dynamics within cancer cells, which are essential for proper cell division. These alkaloids bind to tubulin, the protein subunit that forms microtubules, thereby inhibiting its polymerization into functional microtubules.

They can also promote the depolymerization of existing microtubules. This interference with the dynamic instability of the microtubule network leads to cell cycle arrest specifically at the metaphase stage, ultimately triggering apoptotic cell death.4 The specific binding site for these alkaloids on β-tubulin is known as the Vinca-binding domain.33 The development of semi-synthetic vinca alkaloids such as vinorelbine, vindesine, and vinflunine 4 reflects a strategic effort to improve upon the pharmacological profiles of the naturally occurring compounds. These structural modifications were often designed to enhance antitumor activity against specific cancer types and, importantly, to reduce the significant neurotoxicity that can be a limiting factor in the clinical use of vincristine and vinblastine.27 This iterative process underscores the critical role of medicinal chemistry in optimizing natural product leads for therapeutic applications.

For example, vinorelbine has demonstrated increased selectivity against mitotic microtubules, which are crucial for cell division, compared to axonal microtubules found in nerve cells, at least in vitro.27 This enhanced selectivity is believed to contribute to its decreased neurotoxicity profile when compared to other vinca alkaloids.27 This illustrates a targeted approach to minimizing a specific class of side effects by understanding the drug's differential interactions with various cellular components. Furthermore, vinflunine, a more recent third-generation vinca alkaloid, has shown some evidence of being a less potent inducer of drug resistance in laboratory studies compared to earlier vinca alkaloids.35 Its unique structural features may also enable it to overcome some of the resistance mechanisms that can limit the effectiveness of other drugs in this class.43 Addressing drug resistance is a critical area in cancer chemotherapy, and the development of agents that can circumvent these mechanisms is of significant clinical importance.

Taxanes

Paclitaxel was initially isolated from the bark of the Pacific yew tree (Taxus brevifolia).4 Docetaxel, on the other hand, is a semi-synthetic analog derived from 10-deacetylbaccatin III, a precursor molecule found in the needles of the more readily available European yew (Taxus baccata).4 Both paclitaxel and docetaxel belong to the taxane family of diterpenoids and are the key phytochemicals responsible for the anticancer activity of these drugs.4 Taxanes exhibit a mechanism of action that is distinct from and, in a sense, opposite to that of the vinca alkaloids. Instead of inhibiting microtubule polymerization, paclitaxel and docetaxel promote the assembly of tubulin into microtubules and, critically, stabilize these microtubules by preventing their normal disassembly or depolymerization. This stabilization leads to the formation of abnormally stable and non-functional microtubules within the cell. The disruption of the dynamic reorganization of the microtubule network is essential for the proper segregation of chromosomes during mitosis, and the presence of these stabilized microtubules interferes with this process, ultimately leading to cell cycle arrest and subsequent apoptosis.4

The initial discovery and development of paclitaxel involved a collaborative effort between the United States Department of Agriculture and the National Cancer Institute 21, highlighting the vital role of publicly funded research institutions and interagency cooperation in the advancement of anticancer drug discovery. This successful collaboration underscores the importance of government support for both fundamental and translational research endeavors in the medical field. The subsequent development of docetaxel as a semi-synthetic analog derived from a more abundant precursor in the European yew 4 was a direct response to the limited availability and ecological concerns associated with harvesting the bark of the slow-growing Pacific yew, which was the original source of paclitaxel. This highlights how practical considerations such as sustainability and ensuring a reliable drug supply can drive the development of semi-synthetic alternatives in the realm of natural product drug development. The high demand for paclitaxel in clinical use quickly exceeded the supply that could be sustainably sourced from the Pacific yew. The successful synthesis of docetaxel from a more readily available source not only addressed this critical supply issue but also allowed for potential optimization of its pharmacological properties for improved therapeutic outcomes.

Camptothecins

The parent compound, camptothecin, was initially isolated from the bark of the Chinese happy tree (Camptotheca acuminata).18 The clinically utilized drugs in this class, topotecan and irinotecan, are semi-synthetic derivatives of this natural compound.4 The key phytochemical responsible for the anticancer activity is camptothecin, with topotecan and irinotecan representing its optimized forms for clinical application.4 Camptothecins exert their anticancer effects by specifically inhibiting the activity of topoisomerase I, an essential enzyme that plays a critical role in DNA replication and transcription. Topoisomerase I functions by creating transient single-strand breaks in the DNA molecule to relieve torsional stress that occurs during these processes. Camptothecins bind to the complex formed between topoisomerase I and DNA, effectively preventing the religation (resealing) of these temporary DNA breaks. This interference leads to the accumulation of DNA damage, particularly during the S phase of the cell cycle when DNA replication is actively occurring, ultimately resulting in cell cycle arrest and the induction of apoptosis in the affected cancer cells.4

The initial discovery of camptothecin in 1958 by Monroe Eliot Wall 19 was followed by a considerable period of research and development. It was not until 1996 that topotecan, the first clinically successful derivative of camptothecin, received regulatory approval for use in patients.19 This significant time lag highlights the often lengthy and complex journey involved in translating a promising natural product into an effective and safe medication for clinical use. The parent compound, camptothecin, presented challenges such as poor solubility and significant side effects, which necessitated extensive structural modifications to overcome these limitations while retaining its potent topoisomerase I inhibitory activity. Irinotecan has established itself as a first-line chemotherapy drug for the treatment of metastatic colorectal cancer globally 21, underscoring the substantial clinical impact and therapeutic value of this class of plant-derived agents in the management of a major type of cancer. Its effectiveness in this specific indication demonstrates the successful translation of a natural product lead into a clinically important medicine, addressing a significant unmet medical need in oncology.

Epipodophyllotoxins

The natural precursor for this class of drugs, podophyllotoxin, is found in the roots of the American mayapple (Podophyllum peltatum) and the Himalayan mayapple (Podophyllum hexandrum).4 The chemotherapy drugs that are currently used clinically, etoposide and teniposide, are semi-synthetic derivatives of this lignan.4 Podophyllotoxin is the key phytochemical in the plant, and etoposide and teniposide represent chemically modified versions that have been optimized for therapeutic use.4 Etoposide and teniposide exert their anticancer effects by inhibiting the activity of topoisomerase II, another enzyme that is crucial for DNA replication and repair. Topoisomerase II works by creating transient double-strand breaks in the DNA molecule to facilitate processes such as DNA unwinding and chromosome segregation during cell division. Epipodophyllotoxins stabilize the complex formed between topoisomerase II and DNA, preventing the religation (resealing) of these double-strand breaks. This interference with DNA integrity leads to the accumulation of DNA damage, ultimately resulting in cell cycle arrest and the induction of apoptosis in the affected cancer cells.4 It is noteworthy that while podophyllotoxin itself primarily binds to tubulin and inhibits microtubule assembly, similar to the vinca alkaloids, etoposide and teniposide have a distinct mechanism of action that targets topoisomerase II.4 Early clinical trials involving the direct use of podophyllotoxin were largely unsuccessful due to issues of limited efficacy and significant toxicity in patients.4

This experience underscores the critical importance of structural modification in order to optimize the therapeutic potential of natural products. By altering the chemical structure of podophyllotoxin, researchers were able to develop etoposide and teniposide, which exhibit improved efficacy and a more manageable toxicity profile, allowing them to become valuable components of various chemotherapy regimens. Etoposide and teniposide have demonstrated efficacy in the treatment of a diverse range of cancers, including lymphomas, as well as bronchial and testicular cancers.4 This broad spectrum of activity highlights the versatility of topoisomerase II inhibitors in targeting different types of malignancies, making them important tools in the oncologist's therapeutic armamentarium.

Other Plant-Derived Chemotherapy Agents

Ingenol mebutate (marketed as Picato) is a compound extracted from the sap of the milkweed species Euphorbia peplus.19 It is approved for topical application in the treatment of actinic keratoses, which are precancerous skin lesions.19 Its mechanism of action involves the rapid induction of cell death in the treated cells, as well as the promotion of a localized inflammatory response that contributes to the clearance of the lesion.19 Trastuzumab emtansine (marketed as Kadcyla) represents a sophisticated approach to targeted cancer therapy. It is an antibody-drug conjugate (ADC) where the monoclonal antibody trastuzumab is linked to emtansine (also known as DM1), a potent cytotoxic agent. Trastuzumab specifically targets the HER2 protein, which is overexpressed in certain types of breast cancer. Emtansine is a synthetic derivative of a compound originally isolated from the Ethiopian plant Maytenus ovatus.19 The therapeutic mechanism involves the trastuzumab component specifically binding to HER2-positive cancer cells, leading to the internalization of the entire ADC complex into the cancer cell. Once inside, the cytotoxic emtansine is released, inhibiting microtubule assembly and ultimately leading to the selective death of the HER2-overexpressing cancer cells.19 The development of targeted therapies like antibody-drug conjugates, such as trastuzumab emtansine, signifies a significant advancement in cancer treatment strategies.

By conjugating a potent plant-derived cytotoxic agent to a monoclonal antibody that specifically recognizes a marker on cancer cells, this approach aims to deliver the chemotherapy directly to the tumor site, thereby minimizing exposure and potential toxicity to healthy tissues throughout the body. This represents a significant shift towards more precision-based oncology, where treatments are tailored to the specific characteristics of the cancer.

Recent Research and Emerging Phytochemicals in Cancer Therapy

Recent scientific literature indicates a sustained and growing interest in the potential of phytochemicals for both the prevention and treatment of cancer.44 Numerous reviews highlight the diverse array of phytochemicals currently under investigation and their multifaceted mechanisms of action against cancer cells.44 Many phytochemicals have demonstrated the ability to modulate key signaling pathways that are frequently dysregulated in cancer development and progression, including those involved in cell growth, proliferation, survival, and metastasis.47 These compounds often exert their effects by interacting with multiple molecular targets within these complex pathways. Preclinical studies have highlighted various anticancer effects of phytochemicals, such as the induction of apoptosis (programmed cell death), cell cycle arrest at different stages of cell division, inhibition of cancer cell proliferation, suppression of angiogenesis (the formation of new blood vessels that supply tumors with nutrients and oxygen), and even the modulation of the immune system to enhance the body's natural antitumor responses.7

However, significant challenges remain in translating these promising results from laboratory settings to successful clinical applications in human patients. These hurdles often involve issues related to the poor bioavailability of many phytochemicals, meaning they are not easily absorbed or effectively utilized by the body after administration.46 The complex metabolism of these compounds and their potential interactions with other substances in the body also pose challenges, as does the difficulty in achieving and maintaining effective concentrations of the phytochemicals at the tumor site.

Despite the extensive preclinical evidence supporting the anticancer potential of a vast number of phytochemicals, only a limited fraction of these compounds have successfully transitioned into approved chemotherapy drugs for routine clinical use.46 This discrepancy underscores the significant hurdles that exist in the drug development pipeline, particularly for natural products. There is a critical need for innovative strategies to overcome issues such as bioavailability, target specificity, and the complexity of human physiology to effectively harness the therapeutic power of these natural compounds in cancer treatment. Numerous phytochemicals are currently under intense investigation in preclinical and clinical trials for their potential as anticancer agents.26 These include well-studied compounds such as curcumin, found in turmeric; resveratrol, present in grapes and berries; epigallocatechin gallate (EGCG), abundant in green tea; sulforaphane, derived from cruciferous vegetables; genistein, found in soybeans; quercetin, present in various fruits and vegetables; capsaicin, the active component of chili peppers; silymarin, extracted from milk thistle; berberine, found in Berberis plants; ellagic acid, present in pomegranates and berries; lycopene, abundant in tomatoes; indole-3-carbinol, found in cruciferous vegetables; beta-glucans, derived from oats and mushrooms; allicin, the active compound in garlic; catechins, found in tea and cocoa; ursolic acid, present in apples and cranberries; limonene, from citrus peels; betulinic acid; artemisinin; and thymoquinone, found in black seed.7

These emerging phytochemicals exhibit diverse mechanisms of action, including inhibiting cell proliferation, inducing apoptosis, modulating inflammatory responses, acting as antioxidants, interfering with angiogenesis, and affecting various signaling pathways critical for cancer development.7 They are being investigated for their potential in treating a wide range of cancers in preclinical models. There is also a growing interest in the potential of combining specific phytochemicals with conventional chemotherapy drugs to achieve synergistic anticancer effects, enhance the overall efficacy of treatment, and potentially reduce the severity of chemotherapy-induced side effects.21 This combination therapy approach aims to leverage the different and often complementary mechanisms of action of synthetic drugs and natural compounds to achieve better outcomes for patients. The consistent focus on phytochemicals like curcumin and resveratrol in a significant number of preclinical and increasingly clinical studies 7 suggests a strong scientific rationale for their potential as anticancer agents. Their ability to target multiple pathways involved in cancer development and progression, coupled with their generally favorable safety profiles compared to traditional chemotherapy, makes them particularly promising candidates for further research and development in the field of oncology.

Furthermore, the exploration of whole plant extracts and essential oils 7 in cancer research indicates a growing recognition of the potential synergistic effects that can arise from the complex mixtures of phytochemicals present in these natural sources. Rather than focusing solely on single, isolated compounds, this approach aims to harness the combined therapeutic power of multiple bioactive constituents working together, which may lead to more effective and potentially less toxic anticancer therapies.

1 Cancer Chemotherapy - MedlinePlus, accessed April 12, 2025, https://medlineplus.gov/cancerchemotherapy.html
2 Natural Products | Center for Cancer Research, accessed April 12, 2025, https://ccr.cancer.gov/news/horizons/article/natural-products
3 Natural products for cancer chemotherapy - PMC - PubMed Central, accessed April 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3815406/
4 Natural Products as a Vital Source for the Discovery of Cancer ..., accessed April 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5588531/
5 Plant derived substances with anti-cancer activity: from folklore to practice - Frontiers, accessed April 12, 2025, https://www.frontiersin.org/journals/plant-science/articles/10.3389/fpls.2015.00799/full
6 Aspirin, morphine and chemotherapy: essential medicines powered by plants | Natural History Museum, accessed April 12, 2025, https://www.nhm.ac.uk/discover/essential-medicines-powered-by-plants.html
7 Plants can be game-changers in cancer treatment - 360 - 360info, accessed April 12, 2025, https://360info.org/plants-can-be-game-changers-in-cancer-treatment/
8 Cancer drugs A to Z list, accessed April 12, 2025, https://www.cancerresearchuk.org/about-cancer/treatment/drugs
9 Oncology Drugs Approved by the FDA in January 2025, accessed April 12, 2025, https://www.oncnursingnews.com/view/oncology-drugs-approved-by-the-fda-in-january-2025
10 What New Cancer Drugs Were Approved in 2023? - Oncology Nursing News, accessed April 12, 2025,https://www.oncnursingnews.com/view/what-new-cancer-drugs-were-approved-in-2023

11 Database cancer drugs - Anticancer Fund, accessed April 12, 2025, https://www.anticancerfund.org/en/database-cancer-drugs
12 Oncology (Cancer)/Hematologic Malignancies Approval Notifications - FDA, accessed April 12, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications
13 Cancer Drugs - NCI, accessed April 12, 2025, https://www.cancer.gov/about-cancer/treatment/drugs
14 Verified Clinical Benefit | Cancer Accelerated Approvals - FDA, accessed April 12, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals
15 Ongoing | Cancer Accelerated Approvals - FDA, accessed April 12, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals
16 Drug Approvals and Databases - FDA, accessed April 12, 2025, https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases
17 List of Cancer Chemotherapy Drugs - Navigating Care, accessed April 12, 2025, https://www.navigatingcare.com/library/all/chemotherapy_drugs
18 Anticancer Drug Discovery Based on Natural Products: From Computational Approaches to Clinical Studies - MDPI, accessed April 12, 2025, https://www.mdpi.com/2227-9059/12/1/201
19 Plant sources of anti-cancer agents - Wikipedia, accessed April 12, 2025, https://en.wikipedia.org/wiki/Plant_sources_of_anti-cancer_agents
20 Discovering New Cancer Drugs from Nature - NCI, accessed April 12, 2025, https://www.cancer.gov/news-events/cancer-currents-blog/2019/cancer-drugs-natural-products-nci-program